Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2020 | Highlights in transplantation for myeloma at ASH 2020

Maximilian Merz • 7 Dec 2020

ASH 2020

Multiple Myeloma Carfilzomib Cyclophosphamide Dexamethasone Lenalidomide

CARTITUDE-1 EMN02 FORTE IFM/DFCI2009

Maximilian Merz, MD, Roswell Park Comprehensive Center Institute, Buffalo, NY, discusses his highlights in the field of multiple myeloma from ASH 2020. In particular, he focuses on the sustained importance of autologous stem cell transplantation (ASCT) as standard of care in newly diagnosed patients. Dr Merz highlights results from the FORTE trial (NCT02203643), the EMN02/HO95 trial (NCT01208766) and the IFM/DFCI2009 trial (NCT03679351). Finally, he discusses the updated results from the CARTITUDE-1 study (NCT03548207). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Factors to consider when manufacturing CAR T-cells for patients with R/R multiple myeloma

Maximilian Merz • 10 Dec 2023

CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM

Maximilian Merz • 10 Dec 2023

Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM

Maximilian Merz • 10 Dec 2023

Comparison of the outcomes from CARTITUDE-1 with a real-world external cohort

Maximilian Merz • 24 Mar 2022

Related Videos

Investigating production failure and out-of-specification production of CAR T-cell therapeutics

Nina Worel • 25 Apr 2024

Using MRD to accelerate drug approval in multiple myeloma

Karthik Ramasamy • 28 Apr 2024

Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial

Roberto Mina • 23 Apr 2024

CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma

Eden Biltibo • 15 Apr 2024